PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-90.75%
Both yoy net incomes decline, with VET at -39.43%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
-4.52%
Negative yoy D&A while VET is 4.67%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
87.01%
Some yoy growth while VET is negative at -111.89%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
-378.76%
Negative yoy working capital usage while VET is 166.10%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-378.76%
Negative yoy usage while VET is 166.10%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
149.23%
Well above VET's 213.83%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
-18.13%
Negative yoy CFO while VET is 218.39%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
56.72%
Some CapEx rise while VET is negative at -56.07%. John Neff would see competitor possibly building capacity while we hold back expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
352.24%
Growth well above VET's 36.11%. Michael Burry would suspect heavier intangible or side spending overshadowing competitor’s approach, risking short-term FCF.
64.67%
We have mild expansions while VET is negative at -50.61%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
No Data
No Data available this quarter, please select a different quarter.
252.73%
Stock issuance far above VET's 21.91%. Michael Burry flags a significant dilution risk vs. competitor’s approach unless ROI is very high.
-16320.89%
We cut yoy buybacks while VET is 0.00%. Joel Greenblatt would question if competitor is gaining a per-share edge unless expansions justify holding cash here.